Research programme: autologous T-cell therapy - Lion Biotechnologies

Drug Profile

Research programme: autologous T-cell therapy - Lion Biotechnologies

Alternative Names: HPV TIL; LN 145

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator National Cancer Institute (USA); National Institutes of Health (USA)
  • Developer Lion Biotechnologies Inc; MedImmune; National Cancer Institute (USA)
  • Class T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Bladder cancer; Breast cancer; Cervical cancer; Head and neck cancer; Human papillomavirus infections; Lung cancer; Malignant melanoma

Most Recent Events

  • 20 Dec 2016 Lion Biotechnologies and H. Lee Moffitt Cancer Center and Research Institute enter into a research collaboration for tumour infiltrating lymphocyte
  • 24 Aug 2016 Lion Biotechnologies amends CRADA with the National Cancer Institute for the development of T-cell therapy in Melanoma
  • 01 Feb 2016 US FDA approves IND application for LN 145 in Cervical and Head and neck cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top